Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
01/06/2023 22:17
June 1 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS - ON MAY 25, RECEIVED NOTICE OF
DELISTING
OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ
Source text for Eikon: ID:
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update